Quantcast

Latest Buprenorphine Stories

2014-07-29 08:31:39

MELBOURNE, Australia, July 29, 2014 /PRNewswire/ -- -- Next phase of the TPM®/Oxymorphone clinical development program has commenced -- TPM®/Oxycodone Phase 2a trial to be conducted in Australia during Q4 2014 -- TPM®/Oxymorphone Phase 2 trial to be conducted in the United States in 1H 2015 Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: PPGNY), today provided updates on its opioid transdermal patch programs after its...

2014-07-22 12:29:33

PITTSBURGH, July 22, 2014 /PRNewswire/ -- Community Care Behavioral Health Organization today released guidelines for treatment and recovery practices involving the use of methadone, an opioid used to treat opioid addiction. The guidelines* - titled, "Supporting Recovery from Opioid Addiction: Community Care Best Practice Guidelines for Recovery-Oriented Methadone Maintenance" - are intended to provide direction for physicians, clinicians, agencies, and systems in the Community Care...

2014-07-22 08:31:15

RALEIGH, N.C., July 22, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) announced that its Board of Directors has appointed Charles J. (Chuck) Bramlage and Dr. Barry I. Feinberg as members of the Board. http://photos.prnewswire.com/prnvar/20110217/CL49801LOGO Mr. Bramlage is a veteran pharmaceutical industry executive with extensive experience in marketing, sales and other commercial functions. He is currently the Chief Executive Officer of...

2014-07-16 08:28:03

FDA also approves the use of two Butrans patches for dose adjustments in appropriate chronic pain patients STAMFORD, Conn., July 16, 2014 /PRNewswire/ -- Purdue Pharma L.P. announced that the U.S. Food & Drug Administration (FDA) approved a new 7.5 mcg/hour dosage strength of Butrans(®) (buprenorphine) Transdermal System CIII. Five strengths of Butrans will now be available: 5 mcg/hour, 7.5 mcg/hour, 10 mcg/hour, 15 mcg/hour and 20 mcg/hour. The Butrans Transdermal System is also...

2014-07-10 08:27:14

First and only FDA approved naloxone product specifically indicated for emergency therapy in settings where opioids may be present. RICHMOND, Va., July 10, 2014 /PRNewswire/ -- Kaleo, a privately-held pharmaceutical company headquartered in Richmond, Virginia, today announced the United States (U.S.) commercial availability of EVZIO for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. EVZIO is not a...

2014-07-07 08:27:32

- Pre-NDA meeting scheduled with FDA in July DUBLIN and RALEIGH, N.C., July 7, 2014 /PRNewswire/ -- Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (NASDAQ: ENDP) (TSX: ENL), and BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced today positive top-line results from its pivotal Phase III efficacy study of BEMA buprenorphine in opioid-experienced patients. BEMA buprenorphine is being developed for the management of pain severe enough to require...

2014-07-03 23:01:24

Harbor Village Florida comments on on a study that reduces relapses from heroin. USA (PRWEB) July 03, 2014 Patients that begin treatment for heroin and opioid addiction during hospitalization that also receive outpatient treatment (medical and psychiatric) are 5x less likely to relapse, according to a recent report “Treating Addicted Patients During, After Hospitalization Reduces Relapse” (6/30). According to the report, the average bill for opioid and heroin-related treatment in 2013...

2014-07-01 10:49:46

Boston University Medical Center The results of a new study demonstrate that starting hospitalized patients who have an opioid (heroin) addiction on buprenorphine treatment in the hospital and seamlessly connecting them with an outpatient office based treatment program can greatly reduce whether they relapse after they are discharged. Led by researchers at Boston Medical Center (BMC), the study shows the important role that providers play in offering these patients addiction treatment...

2014-06-21 23:02:03

Las Vegas Rapid Detox Clinic is now offering rapid opiate detox in only 8 hours. Las Vegas (PRWEB) June 21, 2014 Opiate addiction is something that millions of Americans struggle with every day. Now thanks to Las Vegas Detox Clinic’s groundbreaking new procedure, patients can kick their opiate addiction and go through rapid opiate detox without any significant withdrawal symptoms in only eight hours. Battling opiate detox symptoms is the main reason opiate addicts continue using....

2014-06-11 12:26:03

President and CEO Mark A. Sirgo Describes BUNAVAIL(TM) Delivery, Competitive Advantages, Market Size and Patient Need RALEIGH, N.C., June 11, 2014 /PRNewswire/ -- Dr. Mark A. Sirgo, President and Chief Executive Officer of BioDelivery Sciences International, Inc. (NASDAQ: BDSI) was interviewed on Bloomberg TV, TheStreet.com and Business News Network on June 11 regarding BUNAVAIL, BDSI's product for the maintenance treatment of opioid dependence that recently received approval from...


Word of the Day
lambent
  • Licking.
  • Hence Running along or over a surface, as if in the act of licking; flowing over or along; lapping or bathing; softly bright; gleaming.
This word comes the Latin 'lambere,' to lick.
Related